From: Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes
 | 1st quartile | 2nd quartile | 3rd quartile | 4th quartile |
---|---|---|---|---|
Serum osteoprotegerin (pg/ml) a | <5.6 | 5.6-8.4 | 8.5-52.7 | 52.8- 9027 |
  No calcification, n | 26* | 25 | 19 | 16# |
  Calcification, n | 5# | 6 | 12 | 15* |
Serum osteocalcin (ng/ml) b | 0.77-0.82 | 0.83-0.92 | 0.93-1.53 | 1.60-10.56 |
  No calcification, n | 24 | 18 | 21 | 23 |
  Calcification, n | 7 | 13 | 10 | 8 |
Serum FGF23 (pg/ml) c | 10.0-22.7 | 22.9-29.0 | 29.7-40.7 | 42.0- 148.0 |
  No calcification, n | 24 | 20 | 19 | 23 |
  Calcification, n | 7 | 11 | 12 | 8 |
Serum 25-hydroxyvitamin D3 (nmol/l) d | 29.2-48.1 | 48.6-77.3 | 78.6-119.1 | 121.1-239.3 |
  No calcification, n | 20 | 19 | 25 | 22 |
  Calcification, n | 11 | 12 | 6 | 9 |